chemotherapy-induced nausea and vomiting
Oncology · 2009–2023
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| fosnetupitant/palonosetron Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy in… | Mar 2023 | Recommended with restriction | input received |
| netupitant with palonosetron Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly and moderately emetogenic cancer chemotherapy. | Mar 2023 | Recommended with restriction | 1 individuals Society of Hospital Pharmacists of Australia |
| fosnetupitant with palonosetron Prevention of nausea and vomiting associated with cytotoxic chemotherapy in patients receiving moderately or highly emetogenic chemotherapy regimens. | Jul 2020 | Recommended with restriction | none received |
| ondansetron Nausea and vomiting associated with radiotherapy or oral chemotherapy being used to treat malignancy. | Mar 2020 | Recommended with restriction | no section in document |
| aprepitant Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic and moderately emetogenic cancer… | Jul 2019 | Recommended with restriction | no section in document |
| aprepitant Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with carboplatin or oxaliplatin-based regimens from the first… | Mar 2016 | Recommended with restriction | none received |
| fosaprepitant Prevention of nausea and vomiting associated with cytotoxic chemotherapy, including highly emetogenic chemotherapy, breast cancer chemotherapy with… | Nov 2016 | Recommended with restriction | none received |
| netupitant with palonosetron Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC), including secondary… | Nov 2016 | Recommended with restriction | input received |
| netupitant/palonosetron Prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients treated with highly emetogenic chemotherapy for malignancy, and in breast… | Jul 2015 | Recommended with restriction | input received |
| netupitant/palonosetron Prevention of acute and delayed chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy, anthracycline plus cyclophosphamide… | Mar 2015 | Not recommended | none received |
| aprepitant Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with carboplatin or oxaliplatin-based chemotherapy regimens. | Nov 2015 | Not recommended | none received |
| aprepitant Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy in patients who have had a prior episode of chemotherapy-induced… | Mar 2010 | Recommended with restriction | no section in document |
| palonosetron hydrochloride Management of nausea and vomiting associated with cytotoxic chemotherapy being used to treat malignancy which occurs within 48 hours of chemotherapy… | Mar 2010 | Recommended with restriction | no section in document |
| aprepitant Management of nausea and vomiting associated with moderately emetogenic cytotoxic chemotherapy in patients who have had a prior episode of chemotherapy-induced… | Mar 2010 | Recommended with restriction | no section in document |
| aprepitant Prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic cancer chemotherapy. | Nov 2009 | Not recommended | no section in document |
Who spoke
Society of Hospital Pharmacists of Australia
What the PBS pays
$80M in government benefit over 2024–25, across 1,558,020 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| fosnetupitant with palonosetron | $15M |
| fosnetupitant/palonosetron | $15M |
| netupitant with palonosetron | $15M |
| netupitant/palonosetron | $15M |
| palonosetron hydrochloride | $15M |
| ondansetron | $5M |
| fosaprepitant | $0.3M |
| aprepitant | $0.1M |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| granisetronAPO-GRANISETRON granisetron hydrochloride 1mg/1mL injection ampoule | 1997 | 9 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 11 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.